Recent findings have highlighted the role of N6-methyladenosine (m6A) modification in ER+ breast cancer, particularly its capacity to regulate mRNA dynamics, such as the expression of CDK6, a critical mediator in cell cycle progression and a known target of CDK4/6 inhibitors (Xia et al., 2024). Here, CDK6 is linked to breast carcinoma.